Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a major managed Medicare agreement for TONMYA (cyclobenzaprine HCl sublingual tablets), adding approximately 9 million Medicare beneficiaries effective Jan. 1, 2027. Combined with previously announced commercial coverage agreements and broad Medicaid availability, the company said TONMYA will have pharmacy coverage reaching approximately 145 million covered lives, or 46% of the U.S. covered market, while discussions with additional commercial and Medicare payers continue.
Following the expanded coverage and positive launch metrics, Tonix plans to add 50 sales representatives by mid-third quarter 2026, increasing its commercial sales force to approximately 150 people. The company said it is also expanding marketing and medical affairs initiatives to increase awareness of TONMYA as a first-in-class, non-opioid treatment option for fibromyalgia.
TONMYA is the first new treatment for fibromyalgia in more than 15 years, addressing a significant unmet medical need. The expanded coverage is expected to improve patient access to this non-opioid therapy, potentially reducing reliance on opioids for pain management. The move aligns with broader healthcare trends favoring non-addictive pain treatments.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments. The company’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
For more information, visit the company’s newsroom at https://ibn.fm/TNXP.
